ClinicalTrials.gg
RecruitingNCT07575334SSNHL-AcuUpdated May 8, 2026

Acupuncture Therapy for Sudden Sensorineural Hearing Loss

An interventional study of Acupuncture and Sham acupuncture in Sudden Sensorineural Hearing Loss (SSNHL), sponsored by Eye & ENT Hospital of Fudan University. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Eye & ENT Hospital of Fudan University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
256
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Hearing Loss, Sudden with a site in China — 11 open to participants now, 11 under way, 1 of them phase 3. Hearing Loss, Sudden · China.

Planned enrollment
Largest of 15
256 · median 90
Started
2026
with 4 others
No phase
7 of 18
3 open now
Primary completion
2027-12
later than 6 of 10 live
Registered
16th of 18
by date
Lead sponsor
6 of 18
Eye & ENT Hospital of Fudan University

Among the 18 studies in Hearing Loss, Sudden with a site in China, this one has the largest planned enrollment of the 15 interventional ones that give a count, is one of 5 that started in 2026, is one of 7 with no phase, reaches primary completion later than 6 of the 10 other live ones, and was the 16th registered.

Hearing Loss, Sudden

66 studies on the registry are indexed under Hearing Loss, Sudden; 25 are open to participants now.

Browse Hearing Loss, Sudden studies →

Open to participants now

11 of the 18 studies in Hearing Loss, Sudden with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 10 Hearing Loss, Sudden studies recruiting now, 3 (30%) set no upper age limit and 5 (50%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Hearing Loss, Sudden with a site in China, or all of them as a file.
02

Study summary

The goal of this multicenter, prospective, randomized controlled trial is to evaluate the efficacy and safety of acupuncture combined with corticosteroid therapy in treating sudden sensorineural hearing loss (SSNHL). The main questions it aims to answer are:

Does acupuncture combined with corticosteroids improve hearing recovery (pure tone audiometry, PTA) at 8 weeks compared with sham acupuncture combined with corticosteroids? Does this treatment improve secondary outcomes, including tinnitus, dizziness, sleep quality, anxiety, and quality of life? Researchers will compare acupuncture (experimental group) with sham acupuncture (control group) to determine the added therapeutic effect of acupuncture.

Participants will:

  1. Receive either real acupuncture or sham acupuncture 3 times per week for 4 weeks.
  2. Meanwhile, take oral prednisone (1 mg/kg/day, maximum 60 mg/day) for 7 days followed by a 7-day taper.
  3. Undergo hearing tests (PTA, word recognition scores), vestibular function tests, and complete validated questionnaires (SF-36, HADS, ISI, DHI, THI, and TCM symptom scales) at baseline and weeks 1, 2, 4, 8, and 12.
  4. Receive salvage intratympanic steroid injections if hearing does not improve sufficiently by day 14.
03

Conditions studied

  • Sudden Sensorineural Hearing Loss (SSNHL)

Browse trials for

Keywords

  • acupuncture
  • Sudden sensorineural hearing loss (SSNHL)
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 70 years;
  • Meets the diagnostic criteria for sudden sensorineural hearing loss (SSNHL): sudden, unexplained sensorineural hearing loss occurring within 72 hours, with a hearing threshold decrease of ≥30 dB in at least three consecutive frequencies among 250, 500, 1000, 2000, 4000, and 8000 Hz (reference: previous audiologic examination or same frequencies of the contralateral ear);
  • Unilateral SSNHL with self-perceived symmetrical hearing in both ears prior to the current episode (or supported by previous audiologic examination reports);
  • Time from symptom onset to enrollment and treatment initiation within 14 days;
  • Clear consciousness and logical responses, able to understand the scale items and complete the assessments;
  • Agrees to participate in the trial and signs a written form.

Exclusion criteria

Exclusion Criteria:

  • Identifiable definite etiology after complete examination, including acoustic neuroma, cerebrovascular accident, trauma, Hunt syndrome, etc.;
  • History of hearing abnormality (affected ear) or balance dysfunction prior to the current episode (including previous SSNHL, vestibular migraine, Meniere's disease, benign paroxysmal positional vertigo, congenital/hereditary/syphilitic hearing loss, otosclerosis, etc.);
  • Presence of diseases for which systemic therapy is clinically not recommended (e.g., poorly controlled or insulin-dependent diabetes mellitus, history of peptic ulcer, active infection or tuberculosis, history of or C, pancreatitis, severe osteoporosis, osteonecrosis, etc.);
  • Received systemic or local corticosteroid therapy for 10 days or more prior to enrollment;
  • Presence of other diseases (e.g., severe skin disorders) that preclude completion of acupuncture treatment;
  • Presence of severe organ dysfunction;
  • Received acupuncture treatment within the past 12 months;
  • Pregnant or breastfeeding women;
  • Other reasons deemed by the investigator as unsuitable for participation in this clinical study (e.g., high anticipated difficulty in completing follow-up, obvious low compliance, etc.).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
256 participants (estimated)

Study arms

  • Experimental
    Acupuncture combined with corticosteroids group

    Participants in this group will receive real acupuncture 3 times per week for 4 weeks, together with oral prednisone (1 mg/kg/day, maximum 60 mg/day) for 7 days followed by a 7-day taper, plus oral Ginkgo biloba extract for 4 weeks.

    Procedure: Acupuncture

  • Sham comparator
    Sham acupuncture combined with corticosteroids group

    Participants in this group will receive sham acupuncture (applied to the same acupoint locations as in the experimental group, while the needle tip does not penetrate the skin) 3 times per week for 4 weeks, together with oral prednisone (1 mg/kg/day, maximum 60 mg/day) for 7 days followed by a 7-day taper, plus oral Ginkgo biloba extract for 4 weeks.

    Procedure: Sham acupuncture

Interventions

  • ProcedureAcupuncture

    Main Acupoints (Fixed): Tinghui (GB2), Yifeng (SJ17), Tinggong (SI19), and Shuaigu (GB8) on the affected side; Baihui (GV20) at the vertex; Zhongzhu (SJ3) and Zulinqi (GB41) bilaterally. Adjunct Acupoints (Bilateral, selected based on TCM pattern differentiation): External Pathogen Invasion: Hegu (LI4) + Waiguan (SJ5) Liver Fire Harassing Upper: Yanglingquan (GB34) + Xingjian (LR2) Phlegm Fire Stagnation: Fenglong (ST40) + Neiting (ST44) Qi Stagnation and Blood Stasis: Xuehai (SP10) + Taichong (LR3) Kidney Essence Deficiency: Taixi (KI3) + Sanyinjiao (SP6) Spleen and Stomach Deficiency: Zusanli (ST36) + Qihai (CV6)

  • ProcedureSham acupuncture

    The same acupoints are used, but with blunt-tip placebo needles that do not penetrate the skin. The needles are fixed with adhesive patches, and the procedure is identical to the real acupuncture group to maintain blinding.

06

What researchers measure

Primary outcomes

  1. Hearing improvement

    Hearing improvement measured by the change in Pure Tone Audiometry (PTA) average (500, 1000, 2000, and 4000 Hz) from baseline to week 8, compared between the acupuncture + corticosteroid group and the sham acupuncture + corticosteroid group.

    Time frame: Week 8

Secondary outcomes

  1. Hearing outcomes at multiple time points

    Changes in PTA at weeks 1, 2, 4, 8, and 12

    Time frame: week 1, 2, 4, 8, and 12

  2. Word Recognition Score (WRS)

    Changes of WRS from baseline at weeks 1, 2, 4, 8, and 12

    Time frame: weeks 1, 2, 4, 8, and 12

  3. Sudden hearing loss recovery grade

    Complete, significant, partial, or no recovery according to the 2019 AAO-HNS guideline criteria

    Time frame: weeks 1, 2, 4, 8, and 12

  4. TCM symptom score

    Change from baseline to week 8 using the pattern-specific TCM symptom scale

    Time frame: week 8

  5. Sensory Organization Test

    Sensory Organization Test (SOT) scores at weeks 1, 2, 4, 8, and 12

    Time frame: weeks 1, 2, 4, 8, and 12

  6. Insomnia Severity Index (ISI)

    Changes from baseline at weeks 1, 2, 4, 8, and 12

    Time frame: weeks 1, 2, 4, 8, and 12

  7. Dizziness Handicap Inventory (DHI)

    Changes from baseline at weeks 1, 2, 4, 8, and 12

    Time frame: weeks 1, 2, 4, 8, and 12

  8. Tinnitus Handicap Inventory (THI)

    Changes from baseline at weeks 1, 2, 4, 8, and 12

    Time frame: weeks 1, 2, 4, 8, and 12

  9. Hospital Anxiety and Depression Scale (HADS)

    Changes from baseline at weeks 1, 2, 4, 8, and 12

    Time frame: weeks 1, 2, 4, 8, and 12

  10. Quality of life (SF-36)

    Changes from baseline at weeks 1, 2, 4, 8, and 12

    Time frame: weeks 1, 2, 4, 8, and 12

  11. Aural fullness scale (AFS)

    Visual analog scale (0-10) changes from baseline at weeks 1, 2, 4, 8, and 12

    Time frame: weeks 1, 2, 4, 8, and 12

  12. Salvage treatment rate

    Proportion of participants requiring intratympanic steroid injection due to insufficient hearing recovery at day 14

    Time frame: day 14

  13. Safety outcome

    Proportion of adverse events in both groups at week 8

    Time frame: week 8

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Dec 2027, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2026
First posted
May 8, 2026
StartActual
Apr 13, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07575334
Responsible party
Sponsor
First posted
May 8, 2026
Start date
Apr 13, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
May 8, 2026

Study contacts

Weiming Hao, MD, Doctor
Contact
haoweiming1993@163.com
86-18017321721

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion